Gilead Sciences Inc GILD:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD

After Hours: Last | 6:37 PM EST

62.89

+0.10 (+0.16%)

Volume

266,956

62.79

-0.92 (-1.44%)

Volume

7,386,282

52 week range

56.56 - 85.97

...

Loading . . .

KEY STATS

Open63.77
Day High63.97
Day Low62.51
Prev Close63.71
52 Week High85.97
52 Week High Date03/19/20
52 Week Low56.56
52 Week Low Date12/31/20
Market Cap78.709B
Shares Out1.254B
10 Day Average Volume6.92M
Dividend2.84
Dividend Yield4.52%
Beta0.42
1 Year % Change-10.43

RATIOS/PROFITABILITY

EPS (TTM)0.08
P/E (TTM)803.97
Fwd P/E (NTM)8.59
EBITDA (MRQ)3.917B
ROE (MRQ)6.67%
Revenue (MRQ)23.147B
Gross Margin (MRQ)79.02%
Net Margin (MRQ)5.33%
Debt To Equity (MRQ)167.90%

EVENTS

Earnings Date04/28/2021
Ex Div Date03/12/2021
Div Amount0.71
Split Date-
Split Factor-

Latest Gilead Sciences Inc News

February 12, 2021

Worried about hot market? Ride it out with these steady income producers CNBC.com

February 11, 2021

Roche arthritis drug reduces death in severe Covid patients, researchers say CNBC.com

February 10, 2021

European markets close lower as traders digest earnings news; Maersk down 7% CNBC.com

February 5, 2021

Stocks making the biggest moves in the premarket: Peloton, Regeneron, Cardinal Health & more CNBC.com

Latest GILD News From Our Partners

2 Hours Ago

Prometheus Biosciences Starts $125 Million IPO Plan Seeking Alpha

18 Hours Ago

COVID-19 Continues, But Good Times For mRNA Vaccine Developers Pfizer/BioNTech And Moderna Seeking Alpha

February 24, 2021

Predictive Oncology: Potentially Undervalued Drug Discovery AI Company Seeking Alpha

February 23, 2021

CRISPR Therapeutics: Roadblock Ahead Seeking Alpha

February 21, 2021

BioCryst Short-Sellers Lose Control Seeking Alpha

QUOTE FINDER

Market Movers

Profile

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy...

Daniel O'Day

Chairman

Andrew Dickinson

Chief Financial Officer

Jyoti Mehra

Executive Vice President

Brett Pletcher

Executive Vice President

Address

333 LAKESIDE DR

Foster City, CA

94404

United States

https://www.gilead.com/